GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

brolucizumab   Click here for help

GtoPdb Ligand ID: 8713

Synonyms: Beovu® | brolucizumab-dbll | ESBA-1008 | ESBA1008 | RTH258
Approved drug
brolucizumab is an approved drug (FDA (2019), EMA (2020))
Compound class: Antibody
Comment: Brolucizumab is a single-chain variable fragment (scFv) anti-VEGF antibody targeting vascular endothelial growth factor A (VEGFA). This immunobinder was derived from a humanised anti-VEGFA rabbit monoclonal [2].
Peptide sequence and secondary structural information are available from brolucizumab's IMGT/mAb-DB record.
Peptide sequence alignment analysis of patented peptide sequences using the heavy chain variable region of brolucizumab identifies a 100% match with SEQ ID NO: 164 in patent US8349322 B2 [1].

Following regulatory approval brolucizumab took its place as a wet age-related macular degeneration therapy alongside aflibercept (Eylea®) and ranibizumab (Lucentis®), which were previously the main drugs used for this indication. However, with patent protection for both of these older dugs due to expire in the next 2-5 years [4], brolucizumab will likely face competition from aflibercept and ranibizumab biosimilars.
Bioactivity Comments
Given the research code assigned, it is likely that brolucizumab is the derivative designated 578minmaxT84N_V89L (protein1008) in patent US8349322 B2 [1]. Data for 578min_max (protein1008) is provided in the interaction table below.
Selectivity at ligand targets
Key to terms and symbols Click column headers to sort
Target Sp. Type Action Value Parameter Concentration range (M) Reference
VEGFA Primary target of this compound Hs Antibody Binding 8.8 pKd - 1
⤷ pKd 8.8 (Kd 1.59x10-9 M) [1]